Literature DB >> 24750606

Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation.

Shadabul Haque1, Shadab Md2, Mohammad Fazil2, Manish Kumar3, Jasjeet Kaur Sahni2, Javed Ali2, Sanjula Baboota2.   

Abstract

The purpose of the present investigation was to prepare venlafaxine (VLF) loaded chitosan nanoparticles (NPs) to enhance the uptake of VLF to brain via intranasal (i.n.) delivery. VLF loaded chitosan NPs were prepared and characterized for particle size, size distribution, zeta potential, encapsulation efficiency and in vitro drug release. In order to investigate the localization of chitosan NPs in brain and other organs qualitatively confocal laser scanning microscopy technique was carried out using rhodamine-123 (ROD-123) as marker. The levels of VLF in plasma and brain tissues were also determined, the brain/blood ratios of VLF for VLF (i.v.), VLF (i.n.), VLF chitosan NPs (i.n.) were 0.0293, 0.0700 and 0.1612, respectively, at 0.5h, indicative of better brain uptake of VLF chitosan NPs. The higher drug transport efficiency (508.59) and direct transport percentage (80.34) of VLF chitosan NPs as compared to other formulations suggest its better efficacy in treatment of depression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 24750606     DOI: 10.1016/j.carbpol.2012.02.051

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  14 in total

1.  Donepezil HCl Liposomes: Development, Characterization, Cytotoxicity, and Pharmacokinetic Study.

Authors:  Amarjitsing Rajput; Shital Butani
Journal:  AAPS PharmSciTech       Date:  2022-02-11       Impact factor: 3.246

Review 2.  Advances in Nano-Enabled Platforms for the Treatment of Depression.

Authors:  Fadzai P Mutingwende; Pierre P D Kondiah; Philemon Ubanako; Thashree Marimuthu; Yahya E Choonara
Journal:  Polymers (Basel)       Date:  2021-04-29       Impact factor: 4.329

3.  Evaluation of Neuroprotective Effect of Thymoquinone Nanoformulation in the Rodent Cerebral Ischemia-Reperfusion Model.

Authors:  Xiao-Yu Xiao; Ying-Xian Zhu; Ju-Yuan Bu; Guo-Wei Li; Jian-Hui Zhou; Shao-Peng Zhou
Journal:  Biomed Res Int       Date:  2016-09-20       Impact factor: 3.411

Review 4.  Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.

Authors:  Stephanie Andrade; Maria João Ramalho; Maria do Carmo Pereira; Joana A Loureiro
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

Review 5.  Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows.

Authors:  Daniel González-Nieto; Rocío Fernández-Serra; José Pérez-Rigueiro; Fivos Panetsos; Ricardo Martinez-Murillo; Gustavo V Guinea
Journal:  Cells       Date:  2020-04-26       Impact factor: 6.600

6.  Neuroprotective and Antioxidant Effect of Naringenin-Loaded Nanoparticles for Nose-to-Brain Delivery.

Authors:  Shadab Md; Nabil A Alhakamy; Hibah M Aldawsari; Hani Zakaria Asfour
Journal:  Brain Sci       Date:  2019-10-15

7.  Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation.

Authors:  Mohd Yasir; Udai Vir Singh Sara
Journal:  Acta Pharm Sin B       Date:  2014-11-21       Impact factor: 11.413

Review 8.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.

Authors:  Fabio Sonvico; Adryana Clementino; Francesca Buttini; Gaia Colombo; Silvia Pescina; Silvia Stanisçuaski Guterres; Adriana Raffin Pohlmann; Sara Nicoli
Journal:  Pharmaceutics       Date:  2018-03-15       Impact factor: 6.321

Review 9.  Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.

Authors:  Yana Zorkina; Olga Abramova; Valeriya Ushakova; Anna Morozova; Eugene Zubkov; Marat Valikhov; Pavel Melnikov; Alexander Majouga; Vladimir Chekhonin
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

Review 10.  Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.

Authors:  David Lee; Tamara Minko
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.